Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Inclusion Criteria: * Healthy male and female volunteers (female not pregnant, lactating or breastfeeding) * BMI (Body Mass Index) between 19-29 kg/m\^2, both inclusive * Fasting plasma glucose from 70-115 mg/dl * Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data Exclusion Criteria: * Any clinically significant disease history, in the opinion of the Investigator, of systemic or organ disease * Clinically significant abnormalities on pre-study clinical examination or any laboratory measurements during screening * Positive results on screening for Hepatitis B surface antigen, Hepatitis C antibody and HIV (human immunodeficiency virus) antibody * Positive results on the drug abuse/alcohol screen * Any regular use of prescription or nonprescription drugs, including mega-vitamin or herbal supplement regimens, other than contraceptives, that cannot be stopped at least 1 week prior to Visit 2 (trial product dose administration) and for the duration of the study * Subject is currently a smoker (more than one cigarette per day or equivalent) * Use of grapefruit or grapefruit juice within 7 days of trial product dose administration * Blood donation, surgery or trauma with significant blood loss (500 mL) within the last 2 months prior to dosing